Valuation : ProSomnus, Inc.

Market Cap 237K 204K 192K 175K 327K 22.33M 328K 2.26M 878K 11.46M 888K 869K 36.92M P/E 2022
-7.8x
P/E 2023 -0.66x
Enterprise Value 35.24M 30.33M 28.53M 26.06M 48.76M 3.33B 48.89M 337M 131M 1.71B 132M 129M 5.5B EV / Sales 2022
5.49x
EV / Sales 2023 1.85x
Free-Float
90.18%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.004
1.36
5 years 0
Extreme 0.004
11.3
10 years 0
Extreme 0.004
11.3
Manager TitleAgeSince
Chief Executive Officer 52 2022-05-02
Chief Tech/Sci/R&D Officer 45 2022-05-02
Director of Finance/CFO 57 2023-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
2/15/24 Free

Founder

315,742 1.9254%
2/15/24 Free

Chief Financial Officer

315,742 1.9254%
2/15/24 Free

Chief Executive Officer

1,322,756 8.0663%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-98.72% 237K
-0.29%+2.35%-32.44%+20.16% 4.07B
+1.59%-0.39%+54.69% - 1.47B
+0.61%+4.17%+100.49% - 943M
-0.20%-0.20%-19.84%-6.48% 147M
+135.00%0.00% - - 138M
+3.54%-6.09%+58.80%+48.77% 111M
Average +20.04%+0.06%+26.95%-9.07% 983.04M
Weighted average by Cap. +3.02%+1.35%+6.97%+19.99%

Financials

2022 2023
Net sales 19.39M 16.69M 15.7M 14.34M 26.83M 1.83B 26.9M 186M 72M 939M 72.82M 71.24M 3.03B 27.65M 23.79M 22.39M 20.45M 38.26M 2.61B 38.36M 265M 103M 1.34B 104M 102M 4.32B
Net income -7.15M -6.15M -5.78M -5.28M -9.89M -675M -9.91M -68.36M -26.53M -346M -26.83M -26.25M -1.12B -24.1M -20.73M -19.51M -17.82M -33.34M -2.27B -33.43M -231M -89.45M -1.17B -90.48M -88.51M -3.76B
Net Debt 17.17M 14.77M 13.9M 12.7M 23.75M 1.62B 23.81M 164M 63.73M 832M 64.46M 63.05M 2.68B 35.01M 30.12M 28.34M 25.89M 48.43M 3.31B 48.56M 335M 130M 1.7B 131M 129M 5.46B
Logo ProSomnus, Inc.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Employees
136
  1. Stock Market
  2. Stocks
  3. LAAA Stock